Dr Agarwal's Health Care IPO: 10 key points to consider before ₹3,027.26 crore offer opening

Dr Agarwal's Health Care IPO: The initial share sale of Dr Agarwal's Health Care, which investment firms Temasek Holdings and TPG back, will open for public subscription on Wednesday, January 29, 2025. The price band is ₹382 to ₹402 per share. The company's shares will hit the secondary market on February 5.

Dr Agarwal's Health Care IPO: 10 key points to know

• Dr Agarwal's Health Care IPO subscription period: The book-built issue will be live from January 29 to January 31.
• Anchor investors' bidding: The bidding for anchor investors will take place on Tuesday, January 26.
• IPO offer structure: The ₹3,027.26 crore initial public offer is a mix of new equity shares worth ₹300 crore and an offer-for-sale aggregating to ₹2,727.26 crore by promoters and existing shareholders.
• Dr Agarwal's Health Care IPO price band: The company has set a price band of ₹382 to ₹402 per share for the issue.
• Reservation: The eye care services provider has set aside 50% of the net offer for qualified institutional buyers, 35% for retail investors and remaining 15% for non-institutional investors.
• Dr Agarwal's Health Care IPO lot size: Investors can submit an application for at least one lot consisting of 35 shares. The minimum bid amount is ₹14,070.
• Objectives: Proceeds from the fresh issue up to ₹195 crore will be used to pay debt, a part for corporate purposes, and unidentified inorganic acquisitions.
• Book-running lead manager and registrar: Jefferies India, Morgan Stanley India Company, Motilal Oswal Investment Advisors and Kotak Mahindra Capital Company are the issue's book-running lead managers, while Kfin Technologies Limited is the registrar.
• Dr Agarwal's Health Care IPO allotment date: The basis of allotment is expected to be finalised on February 3.
• Dr Agarwal's Health Care IPO listing date: Shares will make their debut on the NSE and the BSE on February 5.

Dr Agarwal's Health Care provides various services, including refractive, cataract, and other surgeries, non-surgical treatments, consultations, diagnosis, and the sale of optical products, accessories, contact lenses and eye-related pharmaceutical items.

It has a network of 193 facilities as of September 2024, with a majority concentration in the Southern part of India, particularly Hyderabad, Bengaluru and Chennai, followed by Western India. It also operates 16 facilities in the African market.

The company revenue from operations stood at ₹1,332.15 crore in the financial year 2023-24 and net profit was ₹95.05 crore.